INCIDENCE OF PELVIC INFLAMMATORY DISEASE AMONG WOMEN WHO ATTENDED GYNAECOLOGICAL CLINIC FROM 2021-2024

Abstract

The study examined the incidence and factors associated with pelvic inflammatory disease (PID) among women attending gynecological clinics from 2021 to 2024. Adopting a quantitative survey research design, data were collected using a structured questionnaire administered to a sample of 120 respondents. The questionnaire encompassed inquiries about PID incidence, demographic and clinical factors, and the effectiveness of preventive measures. SPSS27 was employed to present and analyze the data, with statistical tests such as t-tests used to test hypotheses regarding PID incidence and associated factors. Findings revealed a concerning incidence rate of PID among respondents, with demographic and clinical factors significantly associated with PID occurrence. Additionally, adequate utilization of preventive measures and timely treatment was found to significantly reduce PID incidence. However, limitations such as reliance on self-reported data and the study's cross-sectional design were noted. Despite these limitations, the study underscores the multifaceted nature of PID and the importance of comprehensive approaches to its prevention and management. In conclusion, the study highlights the significance of PID as a public health concern and emphasizes the need for targeted interventions to reduce its incidence and mitigate its adverse effects on women's reproductive health. Recommendations include enhancing public awareness, improving access to healthcare services, strengthening STI screening and treatment protocols, and fostering multidisciplinary collaboration. By addressing these recommendations, policymakers, healthcare providers, and public health officials can work together to improve PID prevention, diagnosis, and management, ultimately enhancing women's reproductive health outcomes.

CHAPTER ONE

INTRODUCTION

1.1 Background to the Study

Pelvic inflammatory disease (PID) is a significant public health concern affecting millions of women worldwide, particularly those in their reproductive years. It is characterized by inflammation of the female reproductive organs, including the uterus, fallopian tubes, and ovaries (Brunham et al., 2021). This condition often results from untreated or inadequately treated sexually transmitted infections (STIs), such as chlamydia and gonorrhea (Stephens et al., 2021). PID can lead to serious complications, including chronic pelvic pain, infertility, ectopic pregnancy, and an increased risk of HIV transmission (Lis et al., 2021). Despite advances in medical knowledge and treatment modalities, the incidence of PID remains substantial, imposing considerable burdens on healthcare systems and individual well-being.

Untreated STIs are a primary risk factor for the development of PID (Eschenbach et al., 2021). Studies have shown that women with a history of STIs, particularly chlamydia and gonorrhea, are at an increased risk of developing PID (Morris et al., 2022). The presence of these infections can lead to ascending infection of the reproductive tract, resulting in inflammation and damage to the pelvic organs (Ratelle et al., 2023). Additionally, factors such as multiple sexual partners, inconsistent condom use, and a young age at first intercourse contribute to the risk of acquiring STIs and subsequently developing PID (Al-Kuran et al., 2021).

In addition to STIs, other factors may predispose women to PID, including the use of intrauterine devices (IUDs) for contraception (Viberga et al., 2021). While IUDs are highly effective and safe contraceptives, they can increase the risk of developing PID, particularly in the first few weeks after insertion (Lee et al., 2020). This risk is thought to be related to the introduction of bacteria into the uterus during insertion or due to changes in the cervical mucus that facilitate bacterial ascent into the upper genital tract (Ádám et al., 2020). However, the overall risk of PID associated with IUD use is low, and the benefits of contraception typically outweigh the potential risks (Grimes, 2020).

The clinical presentation of PID can vary widely, ranging from mild pelvic discomfort to severe abdominal pain and systemic symptoms such as fever and vomiting (Thompson et al., 2020). Diagnosis is often based on a combination of clinical findings, laboratory tests, and imaging studies (Workowski et al., 2021). However, PID can be challenging to diagnose accurately, particularly in its early stages, when symptoms may be subtle or nonspecific (Doxanakis et al., 2020). Therefore, healthcare providers must maintain a high index of suspicion for PID, especially in women with risk factors such as STI exposure or recent gynecological procedures (Wiesenfeld et al., 2023).

Early recognition and prompt treatment of PID are essential to prevent complications and reduce the risk of long-term sequelae (Chow et al., 2021). Antibiotic therapy targeting common pathogens associated with PID, such as Chlamydia trachomatis and Neisseria gonorrhoeae, is the cornerstone of treatment (Howells & Okwudili, 2022). In severe cases or when complications such as tubo-ovarian abscesses are present, hospitalization and surgical intervention may be necessary (Kreisel et al., 2021). Additionally, patients with PID should be counseled on the importance of completing

1.2 Statement of Problem

Despite significant advancements in medical knowledge and treatment modalities, pelvic inflammatory disease (PID) continues to pose a substantial public health burden globally. While PID is a well-recognized condition characterized by inflammation of the female reproductive organs, including the uterus, fallopian tubes, and ovaries, there remain notable gaps in our understanding and management of this condition.

One of the primary challenges in addressing PID lies in its multifactorial etiology. While sexually transmitted infections (STIs) such as chlamydia and gonorrhea are established risk factors for PID (Brunham et al., 2021), there is a need for further research to elucidate additional contributing factors and their interplay in the development of PID. Additionally, the impact of emerging pathogens and antimicrobial resistance on PID incidence and outcomes warrants investigation to inform targeted preventive strategies and treatment approaches (Lis et al., 2021).

Furthermore, there are disparities in PID diagnosis and management, particularly concerning the accessibility and utilization of healthcare services among vulnerable populations. Limited access to gynecological care, inadequate screening practices, and socioeconomic factors contribute to delayed diagnosis and suboptimal treatment of PID, exacerbating its associated morbidity and long-term sequelae (Morris et al., 2022).

Moreover, while antibiotic therapy remains the cornerstone of PID treatment, there is a lack of consensus regarding optimal treatment regimens, particularly in the context of antimicrobial resistance and individual patient factors (Eschenbach et al., 2021). Additionally, the role of adjunctive therapies and novel treatment modalities in improving PID outcomes requires further exploration to enhance patient care and reduce the risk of complications (Thompson et al., 2020).

Addressing these gaps in knowledge and practice is essential to effectively prevent, diagnose, and manage PID. By elucidating the complex etiology of PID, improving access to quality care, and optimizing treatment strategies, we can mitigate the burden of PID on women's health and well-being, ultimately improving reproductive outcomes and reducing healthcare costs associated with PID-related complications.

1.3 Objectives of the Study

The specific objectives of this study were:

1. To determine the incidence rate of pelvic inflammatory disease (PID) among women attending gynecological clinics from 2021 to 2024.

2. To identify the demographic and clinical factors associated with the occurrence of PID among women attending gynecological clinics during the study period.

3. To assess the effectiveness of current preventive and management strategies in reducing the incidence of PID among women attending gynecological clinics.

1.4 Research Questions

1. What is the incidence rate of pelvic inflammatory disease (PID) among women attending gynecological clinics from 2021 to 2024?

2. What demographic and clinical factors are associated with the occurrence of PID among women attending gynecological clinics during the study period?

3. How effective are current preventive and management strategies in reducing the incidence of PID among women attending gynecological clinics?

1.5 Research Hypotheses

1. There is no significant difference in the incidence rate of PID among women attending gynecological clinics between the years 2021 to 2024.

2. Demographic factors such as age, ethnicity, and socioeconomic status are not associated with the occurrence of PID among women attending gynecological clinics.

3. Adequate utilization of preventive measures and timely treatment does not significantly reduces the incidence of PID among women attending gynecological clinics.

1.6 Significance of the Study

The significance of this study lies in its potential to address critical gaps in knowledge regarding pelvic inflammatory disease (PID), thereby making a substantial contribution to public health efforts aimed at reducing its burden and improving reproductive health outcomes for women. By examining PID incidence and associated factors among women attending gynecological clinics from 2021 to 2024, this study holds several important implications for healthcare providers, policymakers, and public health officials.

Firstly, this study's findings will provide updated and comprehensive information on PID incidence trends and demographic and clinical factors associated with its occurrence. This knowledge is crucial for understanding the epidemiology of PID and identifying high-risk populations, which can inform targeted prevention and intervention efforts. By shedding light on the distribution of PID across different demographic groups and clinical characteristics, this study will enable healthcare providers to tailor screening, diagnostic, and treatment strategies to effectively address the needs of at-risk populations.

Secondly, the findings of this study will inform the development of evidence-based guidelines for PID prevention, diagnosis, and management. By evaluating the effectiveness of current preventive measures, such as education on safe sexual practices, promotion of condom use, and screening and treatment of sexually transmitted infections (STIs), this study will identify areas for improvement in PID prevention efforts. Additionally, by assessing the utilization of management strategies, including antibiotic therapy, pain management, and surgical interventions, this study will guide the optimization of clinical practice and the development of standardized protocols for PID management.

Furthermore, this study's significance extends to its implications for public health policy and practice. By informing healthcare providers, policymakers, and public health officials about the effectiveness of current preventive and management strategies, this study will facilitate evidence-based decision-making and resource allocation. The findings of this study will contribute to the development of targeted interventions aimed at reducing PID incidence and mitigating its adverse effects on women's reproductive health. Additionally, by highlighting areas for improvement in PID prevention and management, this study will guide the allocation of resources and the implementation of programs and policies aimed at addressing the root causes of PID and its associated complications.

Moreover, this study's significance lies in its potential to improve reproductive health outcomes and quality of life for women affected by PID. By addressing gaps in knowledge and practice, this study seeks to alleviate the burden of PID on women's health and well-being. Ultimately, by informing policy and practice, this study aims to contribute to the achievement of broader public health goals related to reducing the incidence of PID, improving access to quality care, and promoting reproductive health equity.

1.7 Scope of the Study

This study focused on the incidence of pelvic inflammatory disease (PID) among women who attended gynecological clinics from 2021 to 2024. It included women of reproductive age presenting to gynecological clinics with symptoms suggestive of PID or undergoing screening for sexually transmitted infections (STIs). The study encompassed various demographic and clinical factors potentially associated with PID occurrence, including age, ethnicity, sexual behavior, contraceptive use, and previous history of STIs. Data were collected from multiple gynecological clinics within a specified geographical area, ensuring a diverse sample reflective of the population under study.

1.8 Operational Definition of Terms

Pelvic Inflammatory Disease (PID): A condition characterized by inflammation of the female reproductive organs, including the uterus, fallopian tubes, and ovaries, typically caused by untreated or inadequately treated sexually transmitted infections (STIs).

Incidence Rate: The number of new cases of pelvic inflammatory disease (PID) occurring within a specified population over a defined period, usually expressed as the number of cases per 1,000 or 100,000 women-years at risk.

Demographic Factors: Characteristics of study participants, including age, ethnicity, socioeconomic status, and marital status, which may influence the occurrence of pelvic inflammatory disease (PID).

Clinical Factors: Medical history and clinical features associated with pelvic inflammatory disease (PID), including previous sexually transmitted infections (STIs), contraceptive use, sexual behavior, and reproductive health history.

Gynecological Clinics: Healthcare facilities specializing in the diagnosis, treatment, and management of conditions affecting the female reproductive system, including pelvic inflammatory disease (PID) and sexually transmitted infections (STIs).

Preventive Strategies: Interventions aimed at reducing the risk of pelvic inflammatory disease (PID), including education on safe sexual practices, promotion of condom use, screening and treatment of sexually transmitted infections (STIs), and vaccination against certain pathogens such as human papillomavirus (HPV).

Management Strategies: Approaches to the treatment and control of pelvic inflammatory disease (PID), including antibiotic therapy, pain management, and surgical interventions in cases of severe complications such as abscess formation or ectopic pregnancy.

Effectiveness: The extent to which preventive and management strategies for pelvic inflammatory disease (PID) achieve their intended objectives, including reducing the incidence of new cases, preventing complications, and improving overall reproductive health outcomes among affected individuals.